These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16278010)

  • 1. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
    Antila R; Jalkanen J; Heikinheimo O
    Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we preoperatively risk stratify ovarian masses for malignancy?
    Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
    J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
    Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
    Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
    de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
    Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
    Judson K; McCormick C; Vang R; Yemelyanova AV; Wu LS; Bristow RE; Ronnett BM
    Int J Gynecol Pathol; 2008 Apr; 27(2):182-90. PubMed ID: 18317225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
    Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
    Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
    Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
    Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative clinical and radiological features of metastatic ovarian tumors.
    Bruchim I; Ben-Harim Z; Piura E; Tepper R; Fishman A
    Arch Gynecol Obstet; 2013 Sep; 288(3):615-9. PubMed ID: 23471547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.
    Ramirez PT; Slomovitz BM; McQuinn L; Levenback C; Coleman RL
    Gynecol Oncol; 2006 Dec; 103(3):888-90. PubMed ID: 16806436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.